Trisalus Life Sciences, Inc.

This early-stage study tested a new drug called SD-101, delivered directly to the liver, for adults with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if SD-101 was safe and tolerable when given alone or combined with standard immunotherapy …

This early-stage study tested a new drug called SD-101, delivered directly into the liver's main artery, for people with advanced liver cancer. It aimed to see if combining this local treatment with standard immunotherapy drugs was safe and could help control the cancer. The tria…